In a thrilling discovery, two Indian-American researchers have identified a new potential therapeutic target for controlling high blood sugar - a finding that could help millions suffering from type 2 diabetes worldwide.
Researchers showed that lipid molecules called phosphatidic acids enhance glucose production in the liver.
The findings suggest that inhibiting or reducing production of phosphatidic acids may do the opposite.
"This study establishes a role for phosphatidic acids in enhancing glucose production by the liver and identifies enzymes involved in the synthesis of phosphatidic acids as potential drug targets," explained Anil Agarwal, a professor of internal medicine at University of Texas' Southwestern Medical Centre.
These observations were made while studying a mouse model of lipodystrophy, a rare metabolic disease in which the body is devoid of fat.
Lipodystrophy patients often develop diabetes and accumulate fat in the liver because of an imbalance in the body's ability to properly regulate lipids and glucose.
The causal gene 'AGPAT2' which is involved in the synthesis of phosphatidic acid and triglycerides, was removed in the mice - resulting in rodents with generalised lipodystrophy.
The research team then examined what impact this genetic manipulation had on phosphatidic acids and glucose production.
"We expected the levels of phosphatidic acids to go down. However, in examining the livers of these lipodystrophic mice, we unexpectedly found high levels of this lipid class," added lead author Shireesha Sankella, a post-doctoral researcher in the division of nutrition and metabolic diseases.
This led to the identification of new targets involved in the production of phosphatidic acids.
The buildup of these lipid molecules was due to an increase in the levels of two enzymes in the liver - diacylglycerol kinase and phospholipase D.
Researchers also discovered a marked increase in glucose production in the livers of the lipodystrophic mice.
The lack of normal insulin signaling in these lipodystrophic mice led to unrestricted production of phosphatidic acid, contributing to development of hyperglycemia or high blood sugar.
"Besides revealing a new potential therapy to test for treatment of diabetes, the findings may have implications in understanding how cancer develops," Agarwal noted.
Increased phosphatidic acid levels may play an important role in a metabolic pathway that supplies energy to cancer cells, said the study published in the Journal of Biological Chemistry.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
